Oral anticoagulants can prevent thrombotic events and save lives in patients with atrial fibrillation (AF) and other conditions, but they don’t in and of themselves make patients feel better. As such, ...
Although UFH has been the mainstay therapy for extracorporeal anticoagulation for many decades, low-molecular-weight heparins (LMWHs) have now replaced UFH as the anticoagulant of choice in many ...
On October 19, 2010, the Food and Drug Administration (FDA) approved dabigatran for the reduction of the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Approval ...
In this issue of Journal of Oncology Practice, the review by Sorigue and Miljkovic 1 on thromboembolic risk in patients with cancer with atrial fibrillation (AF) and the available anticoagulation ...
For patients younger than 21 who have provoked venous thromboembolism (VTE), shortening the length of anticoagulation to prevent a recurrent event is no worse than using it for the standard 3 months, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results